State of Digital Biology & TechBio (March 2026): New Initiatives, Products, Regulations, Wins & Failures
Evo Long-Context Genomic Foundation Model in Science, Lilly + Insilico $2.75B Expansion, Basecamp Research & BenevolentAI Restructuring
Executive Summary
March 2026 featured the publication of the Evo genomic foundation model, Eli Lilly's expanded multi-target collaboration with Insilico Medicine, and BenevolentAI's strategic restructuring.
Key Findings
**New Initiatives:** Eli Lilly expanded its AI drug discovery collaboration with Insilico Medicine; Merck and Mayo Clinic launched an AI precision medicine alliance; Tecan partnered with NVIDIA on autonomous lab robotics.
**New Products:** Arc Institute and Stanford published the Evo striped-hyena genomic foundation model capable of single-nucleotide resolution across whole prokaryotic genomes; Basecamp Research launched its biodiversity gene atlas.
**Regulations:** EMA and FDA issued joint reflections on real-world evidence (RWE) and electronic health record data quality for oncology label expansions.
**Success Stories:** MindRank dosed the first patient in a Phase III trial of its AI-designed GLP-1 receptor agonist; Earendil Labs secured major biologics co-development backing.
**Failure Stories & Post-Mortems:** BenevolentAI delisted from Euronext Amsterdam following the mid-stage failure of BEN-2293 in atopic dermatitis, serving as an early warning against SPAC-era valuations detached from clinical Phase II proof-of-concept.
1. New Initiatives & Pharma Partnerships (March 2026)
Eli Lilly deepened its partnership with Insilico Medicine while Tecan and NVIDIA teamed up to embed GPU vision and scheduling agents into liquid-handling workcells.
2. New Products (Whole-Genome Foundation Models)
The Evo genomic language model demonstrated zero-shot prediction of essential genes and regulatory elements across 131-kilobase context windows at single-nucleotide resolution.
3. Regulatory Developments
FDA and EMA harmonized data provenance standards for clinicogenomic real-world data used in regulatory submissions.
4. Verified Success Stories
Basecamp Research's environmentally sampled protein database expanded training diversity beyond biased model-organism UniProt sequences, improving enzyme design hit rates.
5. Failure Stories & Capital Market Reckoning
BenevolentAI's delisting from Euronext Amsterdam after falling from a £1.3B SPAC valuation crystallized the market's shift away from literature knowledge graphs toward closed-loop wet-lab perturbation data.
Methodology
Every Monthly State of Affairs report audits five mandatory pillars: (1) New Initiatives & Alliances, (2) New Products & Foundation Models, (3) Regulatory & Compliance Shifts, (4) Verified Success Stories & Clinical Wins, and (5) Failure Stories, Clinical Setbacks & Engineering Post-Mortems.
Conclusions
- •**New Initiatives:** Eli Lilly expanded its AI drug discovery collaboration with Insilico Medicine; Merck and Mayo Clinic launched an AI precision medicine alliance; Tecan partnered with NVIDIA on autonomous lab robotics.
- •**New Products:** Arc Institute and Stanford published the Evo striped-hyena genomic foundation model capable of single-nucleotide resolution across whole prokaryotic genomes; Basecamp Research launched its biodiversity gene atlas.
- •**Regulations:** EMA and FDA issued joint reflections on real-world evidence (RWE) and electronic health record data quality for oncology label expansions.
- •**Success Stories:** MindRank dosed the first patient in a Phase III trial of its AI-designed GLP-1 receptor agonist; Earendil Labs secured major biologics co-development backing.
- •**Failure Stories & Post-Mortems:** BenevolentAI delisted from Euronext Amsterdam following the mid-stage failure of BEN-2293 in atopic dermatitis, serving as an early warning against SPAC-era valuations detached from clinical Phase II proof-of-concept.
Recommendations
- 1**Audit Target Causality Before Scaling Chemistry:** Pair generative chemistry with human genetic and single-cell perturbation evidence to avoid Phase II efficacy attrition.
- 2**Maintain 21 CFR Part 11 & Context-of-Use Provenance:** Align all preclinical and CMC AI models with the FDA's 2026 Risk-Based Credibility Assessment framework.